vs
Side-by-side financial comparison of FINANCIAL INSTITUTIONS INC (FISI) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $62.7M, roughly 1.4× FINANCIAL INSTITUTIONS INC). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -2.0%).
The Mizuho Financial Group, Inc. , known from 2000 to 2003 as Mizuho Holdings and abbreviated as MHFG or simply Mizuho, is a Japanese banking holding company headquartered in the Ōtemachi district of Chiyoda, Tokyo, Japan. The group was formed in 2000–2002 by merger of Dai-Ichi Kangyo Bank, Fuji Bank, and Industrial Bank of Japan. The name mizuho (瑞穂) literally means "abundant rice" in Japanese and "harvest" in the figurative sense.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FISI vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.7M | $86.8M |
| Net Profit | $21.0M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 33.5% | — |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | 24.3% | — |
| EPS (diluted) | $1.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $62.7M | — | ||
| Q4 25 | $64.1M | $86.8M | ||
| Q3 25 | $63.8M | $67.5M | ||
| Q2 25 | $59.7M | $60.0M | ||
| Q1 25 | $57.2M | $49.3M | ||
| Q4 24 | $41.6M | $73.7M | ||
| Q3 24 | $50.1M | $58.6M | ||
| Q2 24 | $65.2M | $31.1M |
| Q1 26 | $21.0M | — | ||
| Q4 25 | $20.0M | — | ||
| Q3 25 | $20.5M | $-91.3M | ||
| Q2 25 | $17.5M | $-111.7M | ||
| Q1 25 | $16.9M | $-116.2M | ||
| Q4 24 | $-82.8M | — | ||
| Q3 24 | $13.5M | $-83.5M | ||
| Q2 24 | $25.6M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 37.4% | -84.7% | ||
| Q3 25 | 39.5% | -140.7% | ||
| Q2 25 | 36.0% | -189.8% | ||
| Q1 25 | 36.0% | -245.8% | ||
| Q4 24 | -276.9% | -117.5% | ||
| Q3 24 | 29.0% | -152.1% | ||
| Q2 24 | 46.2% | -327.6% |
| Q1 26 | 33.5% | — | ||
| Q4 25 | 38.3% | — | ||
| Q3 25 | 32.1% | -135.3% | ||
| Q2 25 | 29.3% | -186.2% | ||
| Q1 25 | 29.5% | -235.5% | ||
| Q4 24 | -198.9% | — | ||
| Q3 24 | 26.9% | -142.7% | ||
| Q2 24 | 39.3% | -312.2% |
| Q1 26 | $1.04 | — | ||
| Q4 25 | $0.96 | — | ||
| Q3 25 | $0.99 | — | ||
| Q2 25 | $0.85 | $-0.33 | ||
| Q1 25 | $0.81 | $-0.36 | ||
| Q4 24 | $-5.32 | $-0.24 | ||
| Q3 24 | $0.84 | $-0.28 | ||
| Q2 24 | $1.62 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $85.5M | $297.0M |
| Total DebtLower is stronger | $114.0M | — |
| Stockholders' EquityBook value | — | $698.6M |
| Total Assets | $6.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $85.5M | — | ||
| Q4 25 | $108.8M | $297.0M | ||
| Q3 25 | $185.9M | $300.8M | ||
| Q2 25 | $93.0M | $301.2M | ||
| Q1 25 | $167.4M | $359.7M | ||
| Q4 24 | $87.3M | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M |
| Q1 26 | $114.0M | — | ||
| Q4 25 | $193.7M | — | ||
| Q3 25 | $115.0M | — | ||
| Q2 25 | $115.0M | — | ||
| Q1 25 | $124.9M | — | ||
| Q4 24 | $124.8M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $124.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $628.9M | $698.6M | ||
| Q3 25 | $621.7M | $702.3M | ||
| Q2 25 | $601.7M | $698.5M | ||
| Q1 25 | $589.9M | $767.9M | ||
| Q4 24 | $569.0M | $710.4M | ||
| Q3 24 | $500.3M | $773.5M | ||
| Q2 24 | $467.7M | $768.5M |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $913.2M | ||
| Q3 25 | $6.3B | $904.9M | ||
| Q2 25 | $6.1B | $907.4M | ||
| Q1 25 | $6.3B | $966.7M | ||
| Q4 24 | $6.1B | $910.4M | ||
| Q3 24 | $6.2B | $991.1M | ||
| Q2 24 | $6.1B | $964.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $-52.6M | ||
| Q3 25 | $-6.9M | $-78.7M | ||
| Q2 25 | $-5.7M | $-67.4M | ||
| Q1 25 | $10.0M | $-103.7M | ||
| Q4 24 | $77.1M | $-73.3M | ||
| Q3 24 | $2.1M | $-59.0M | ||
| Q2 24 | $35.7M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $13.3M | $-61.9M | ||
| Q3 25 | $-7.9M | $-89.5M | ||
| Q2 25 | $-7.3M | $-74.9M | ||
| Q1 25 | $9.2M | $-109.9M | ||
| Q4 24 | $72.2M | $-77.5M | ||
| Q3 24 | $-299.0K | $-61.3M | ||
| Q2 24 | $34.7M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 20.7% | -71.3% | ||
| Q3 25 | -12.4% | -132.7% | ||
| Q2 25 | -12.3% | -124.9% | ||
| Q1 25 | 16.1% | -222.8% | ||
| Q4 24 | 173.3% | -105.1% | ||
| Q3 24 | -0.6% | -104.6% | ||
| Q2 24 | 53.3% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | 10.7% | ||
| Q3 25 | 1.6% | 16.1% | ||
| Q2 25 | 2.7% | 12.4% | ||
| Q1 25 | 1.4% | 12.6% | ||
| Q4 24 | 11.9% | 5.7% | ||
| Q3 24 | 4.9% | 3.9% | ||
| Q2 24 | 1.5% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.94× | — | ||
| Q3 25 | -0.34× | — | ||
| Q2 25 | -0.33× | — | ||
| Q1 25 | 0.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 1.39× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FISI
| Net Interest Income | $52.0M | 83% |
| Noninterest Income | $10.7M | 17% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
